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ABSTRACT
Patients with advanced bladder cancer have poor outcomes, indicating a need for 
more efficient therapeutic approaches. This study characterizes proteomic changes 
underlying bladder cancer invasion aiming for the better understanding of disease 
pathophysiology and identification of drug targets. High resolution liquid chromatography 
coupled to tandem mass spectrometry analysis of tissue specimens from patients 
with non-muscle invasive (NMIBC, stage pTa) and muscle invasive bladder cancer 
(MIBC, stages pT2+) was conducted. Comparative analysis identified 144 differentially 
expressed proteins between analyzed groups. These included proteins previously 
associated with bladder cancer and also additional novel such as PGRMC1, FUCA1, BROX 
and PSMD12, which were further confirmed by immunohistochemistry. Pathway and 
interactome analysis predicted strong activation in muscle invasive bladder cancer of 
pathways associated with protein synthesis e.g. eIF2 and mTOR signaling. Knock-down 
of eukaryotic translation initiation factor 3 subunit D (EIF3D) (overexpressed in muscle 
invasive disease) in metastatic T24M bladder cancer cells inhibited cell proliferation, 
migration, and colony formation in vitro and decreased tumor growth in xenograft 
models. By contrast, knocking down GTP-binding protein Rheb (which is upstream of 
EIF3D) recapitulated the effects of EIF3D knockdown in vitro, but not in vivo. Collectively, 
this study represents a comprehensive analysis of NMIBC and MIBC providing a resource 
for future studies. The results highlight EIF3D as a potential therapeutic target. 
INTRODUCTION
Bladder Cancer (BC) is the second most frequently 
reported malignancy of the genitourinary system, with an 
estimate of 429,800 new cases and 165,100 deaths in 2012 
[1, 2]. Based on the penetration depth into the bladder 
wall, 70% of the newly diagnosed tumors are classified 
as non-muscle invasive bladder cancer (NMIBC, stages 
pTa, pT1, pTis) and are treated by transurethral resection 
and intravesical therapies [3]; whereas the remaining 30% 
are categorized as muscle invasive bladder cancer (MIBC, 
stages pT2-4) and are treated by radical cystectomy, 
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(neo)adjuvant chemotherapy or (chemo) radiotherapy 
[4–6]. Patients harboring MIBC are associated with poor 
outcome: when the cancer is diagnosed at a localized stage 
(cancer has not spread beyond the bladder wall), the 5-year 
survival rate is 47% for patients with muscle-invasive 
disease in comparison to 81% in the case of non-muscle 
invasive disease [7]. Considering the severity of the 
disease, some novel therapies are currently investigated in 
clinical trials, including cancer immunotherapies targeting 
proteins such as programmed cell death protein 1 (PD-1), 
cytotoxic T-Lymphocyte associated protein 4 (CTLA-4) 
[8]; cell cycle checkpoint inhibitors targeting Aurora 
kinase A [9] and signal transduction inhibitors targeting 
fibroblast growth factor receptors (FGFR) [10]. 
To date, extensive efforts have been made to 
characterize the molecular background of BC [11]. Early 
efforts in the interpretation of BC molecular profiling data 
recapitulated a dual-track model, which proposes that 
the disease develops via two distinct forms [12, 13]. The 
papillary NMIBCs originate from urothelial hyperplasia 
as a result of the alteration of the phosphatidylinositol 
3-kinase (PI3K)- protein kinase B (Akt)-mTOR (PI3K-
AKT-mTOR) pathway, mutations in FGFR3 and HRas 
proto-oncogene [14]. On the other hand, the non-papillary 
MIBCs are developing from flat dysplasia and carcinoma 
in situ (CIS) and are characterized by genetic alterations 
in tumor suppressor genes such as tumor protein p53 
(TP53), cyclin dependent kinase inhibitor 2A (CDKN2A), 
Cyclin D1 (CCND1), cyclin dependent kinase inhibitor 1B 
(CDKN1B) and RB transcriptional corepressor 1 (RB1) 
[14]. Although, this model explains many features of BC, 
it does not adequately address the heterogeneity of the 
disease [13]. Emerging evidence from next-generation 
sequencing data, mainly from MIBC, indicates its high 
phenotypic diversity and sub-clonal cancer evolution 
[11, 15–20]. Consequently, the presence of distinct 
molecular disease subtypes have been suggested by 
various groups (as summarized in [19, 21]) opening up 
new research avenues towards better patient stratification 
and tailored therapy selection [22]. 
Investigations at the protein level are attractive, 
since proteins manifest the functional state of the disease-
related molecular alterations and are direct targets 
for pharmaceutical intervention [23]. Tissue samples 
represent the site of cancer initiation and progression and, 
therefore, serve as a very appropriate biological source 
for studying disease-associated alterations. Currently, 
there is a growing number of studies exploring BC tissue 
specimens using proteomics techniques [24–34]. Over 
the past years, emphasis has been placed on investigating 
the differences between BC and the adjacent normal 
urothelial tissue or non-cancerous specimens. As a result 
of these studies, novel biomarkers for cancer diagnosis 
[e.g. stathmin 1 (STMN1), transgelin 2 (TAGLN2) [25]] 
or potential targets for therapeutic intervention were 
proposed (e.g. phosphoglycerate mutase 1 (PGAM1) [24]). 
Furthermore, efforts have been made towards the proteomic 
characterization of individual profiles of NMIBC and MIBC 
[27, 31, 32, 34], in the context of both cellular and stromal 
changes. For example, comparative proteomic analysis of 
non-muscle invasive cancer cells and normal urothelial 
cells revealed changes in pathways related to oxidative 
phosphorylation, focal adhesion, ribosome biogenesis, 
and leukocyte transendothelial migration [31]. In a follow-
up study, proteomic characterization of NMIBC was 
performed, aiming at the investigation of cellular (purified 
normal urothelial cells versus non-muscle invasive cancer 
cells) and stromal changes (normal stromal cells versus 
non-muscle invasive cancer stromal cells) [27]. Alteration 
of several pathways was predicted including metabolic 
pathways, endocytosis, oxidative phosphorylation, and 
spliceosome function [27]. In another study, Niu et al. 
performed a global characterization of the stromal proteome 
of MIBC [32]. Pathway analysis of differentially expressed 
proteins between cancer and normal stromal cells indicated 
changes in metabolic pathways, actin cytoskeleton 
remodeling, adhesion, and endocytosis [32]. Changes in 
focal adhesion and extracellular matrix (ECM)-receptor 
interaction, based on analysis of stromal cells from MIBC 
were associated with the risk of cancer metastasis [34].
A comprehensive, high resolution, direct comparison 
of tissue proteomic profiles between NMIBC and MIBC 
has not been performed yet, to the best of our knowledge. 
Moreover, using the tissue adjacent to the tumor as normal 
control might not be an optimal experimental set up to 
discover what molecular changes make BC aggressive, 
as these areas have frequently cancer-related genetic 
characteristics [35]. Therefore, when aiming at the 
investigation of the molecular events underlying disease 
progression and subsequently key molecules that could 
also be “druggable” targets for therapeutic intervention, 
evaluation of tissue specimens that represent different 
stages of disease appears to be well justified. 
The main objective of this study was the global 
characterization of the proteomic changes underlying BC 
invasion that could ultimately lead to a better understanding 
of disease pathophysiology and subsequent identification 
of biology-driven therapeutic targets. Towards that end, a 
comparative proteomic analysis of tissue specimens from 
NMIBC and MIBC was conducted. In silico analysis of 
differentially expressed proteins predicted, among others, 
a significant up-regulation of protein synthesis. By using in 
vitro assays and in vivo models, the functional relevance of 
eukaryotic translation initiation factor 3 subunit D (EIF3D) 
was evaluated in detail. 
RESULTS
Tissue proteomic profiling
Untargeted proteome analysis of BC tissue 
specimens (NMIBC; pTa, n = 5 versus MIBC pT2+ n = 6) 
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was performed using high resolution liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS) 
analysis in combination with two different software 
packages for protein identification and quantification, in 
order to maximize the reliability of differential protein 
expression analysis (workflow presented in Figure 1). As 
shown (Figure 1), comparable numbers of proteins were 
identified in the experimental groups (pTa and pT2+) by 
both software packages (Proteome Discoverer, PD, and 
Trans Proteomic Pipeline, TPP). To increase the reliability 
of the subsequent differential expression analysis, only 
proteins detected in ≥ 60% of specimens (3/5 for pTa 
and 4/6 for pT2+) in at least one group (pTa, pT2+) were 
considered further. Proteins were defined as differentially 
expressed between the two groups based on statistical 
significance (p < 0.05, independent sample t-test; Figure 1). 
As depicted in Figure 1, sixty proteins were statistically 
significant according to both approaches (PD and TPP) and 
were considered of high validity and reliability. Thus, for 
these proteins thorough literature mining was performed to 
identify novel proteins associated with BC invasion (listed 
in Supplementary Table 1). Numerous proteins previously 
associated with BC were part of this list including, but 
not limited to hydroxyprostaglandin dehydrogenase 
15-(NAD) (HPGD) [36], thymidine phosphorylase 
(TYMP) [37], annexins (e.g. ANXA1 [38], ANXA5 [39], 
ANXA10 [40]), alpha actinins (ACTN) (e.g. ACTN1 [41], 
ACTN4 [42, 43]), membrane-associated progesterone 
receptor component 1 (PGRMC1) [44], transforming 
growth factor-beta-induced protein ig-h3 (TGFBI) [45], 
cadherin 13 (CDH13) [46], or cathepsin E (CTSE) [47], 
serving as a positive control for the performed study. 
In addition, proteins that have been related to other 
cancers but not to BC yet, were also identified, such as 
fibulin-2 (FBLN2), tissue alpha-L-fucosidase (FUCA1), 
staphylococcal nuclease domain-containing protein 1 
(SND1), and EIF3D. Importantly, we also identified 
differentially expressed proteins not yet described in BC 
or other types of malignancy, such as BRO1 domain-
containing protein BROX (BROX), vesicle-trafficking 
protein SEC22b (SEC22B), RNA 3′-terminal phosphate 
cyclase (RTCA) (described below in more detail). A 
detailed categorization of the proteomics findings with 
the representative references supporting their grouping 
is presented in Supplementary Table 1. We subsequently 
performed validation of the differential expression of some 
of the proteins that had not been previously linked to BC or 
BC tissue using immunohistochemistry analysis of a small, 
yet new (e.g. not used for the proteomic analysis) set of 
tissue samples. Based on appropriate antibody availability 
(as confirmed by using Western blot, data not shown), 
the difference in the expression level between MIBC 
and NMIBC could be confirmed for FUCA1, BROX, 
PGRMC1 and 26S proteasome non-ATPase regulatory 
subunit 12 (PSMD12). As shown in Figure 2, in agreement 
with the proteomics results, a decline in the expression 
levels of the former 3 proteins in invasive versus non-
invasive cancers could be observed, reaching statistical 
significance in the case of BROX, and FUCA1, whereas 
a statistically significant up-regulation was observed in the 
case of PSMD12.
Assessment of biological relevance of proteomics 
findings 
To assess the biological relevance of the observed 
molecular changes in BC invasion and predict potentially 
new targets, in silico pathway and interactome analyses 
of the differentially expressed proteins was performed. To 
maximize coverage, the list of 60 proteins was expanded 
to include proteins found to be differentially expressed 
(statistically significant) by one quantification strategy and 
characterized by the same expression trend (up- or down- 
regulation and at least 1.5 fold change) in the second. 
Applying these criteria, 144 proteins were identified 
as differentially regulated between the two groups 
(Supplementary Table 2; full datasets per quantification 
approach are available in Supplementary Table 3). 
Seventy-three out of the 144 proteins were mapped to 208 
pathways, 52 of which were predicted to be significantly 
altered (p < 0.05, right-tailed Fisher Exact Test) in 
MIBC. Pathways with at least 3 molecules assigned were 
prioritized according to the significance level (p < 0.05) 
and the top 20 findings are presented in Table 1. These 
included pathways related to protein synthesis [i.e. 
eukaryotic initiation factor 2 (eIF2) signaling, mammalian 
target of rapamycin kinase (mTOR) signaling, tRNA 
charging, regulation of eukaryotic initiation factor 4 
(eIF4) and ribosomal protein S6 kinase beta-1 (p70S6K) 
signaling], endocytosis (i.e. caveolar and clathrin-mediated 
endocytosis signaling), cell-ECM interactions, cytoskeletal 
remodeling, cell adhesion (i.e. integrin signaling, actin 
cytoskeleton signaling, paxillin signaling, remodeling 
of epithelial adherens junctions, epithelial adherens 
junction signaling), oxidative response / xenobiotic 
metabolism [nuclear factor, erythroid 2 like 2 (NRF2)-
mediated oxidative stress response, glutathione-mediated 
detoxification, aryl hydrocarbon receptor signaling], and 
angiogenesis [vascular endothelial growth factor (VEGF) 
signaling]. High consistency in the expression trend (up-/
down-regulation in MIBC versus NMIBC) of molecules 
mapped to the pathways was most evident for pathways 
targeting protein synthesis including eIF2 signaling, tRNA 
charging, regulation of eIF4 and p70S6K, as well as mTOR 
signaling (Table 1). All proteins mapped to these pathways 
were up-regulated in MIBC, with an exception of 5ʹ-AMP-
activated protein kinase subunit gamma-2 (PRKAG2) 
which was down-regulated in MIBC. However, the down-
regulation of PRKAG2 is expected, when the mTOR 
pathway is activated [48] (Supplementary Figure 1). 
A parallel analysis of predicted protein-protein 
interactions revealed that 97 out of the aforementioned 
Oncotarget69438www.impactjournals.com/oncotarget
144 proteins are involved in an interactome network (261 
interactions were retrieved), as shown in Figure 3. In line 
with the pathway analysis, multiple proteins associated with 
the interactome network create functional clusters related 
to protein synthesis (e.g. EIF3D, numerous ribosomal 
subunits), protein degradation [e.g. polyubiquitin-B (UBB), 
enzymes such as ubiquitin carboxyl-terminal hydrolase 
isozyme L3 (UCHL3), ubiquitin-conjugating enzyme 
E2 D3 (UBE2D3), numerous subunits of proteasome], 
glutathione detoxification (e.g. glutathione transferases), 
Table 1: The top 20 pathways, with at least 3 molecules assigned, predicted based on proteomics 
data
Pathway p-value # associated 
molecules
Pathway Activation 
(z-score)
Molecules
Up-regulated in MIBC
Down-regulated in 
MIBC
Protein synthesis-related pathways:
EIF2 Signaling 6.9E-07 10/185
Activated (2.24) RPL12, RPS13, EIF3D, RPS9, 
RPS18, RPL22, RPL31, RPS14, 
RPL27A, RPL10A
tRNA Charging 2.5E-03 3/39 TARS, VARS, WARS
Regulation of eIF4 and p70S6K 
Signaling 3.6E-03 5/146
RPS13, EIF3D, RPS9, RPS18, 
RPS14
mTOR Signaling 2.0E-03 6/188 RPS13, EIF3D, RPS9, RPS18, 
RPS14
PRKAG2
Oxidative response/xenobiotic metabolism -related pathways:
NRF2-mediated Oxidative 
Stress Response
5.5E-07 10/180 Activated (1.00) EPHX1, FTL, PPIB, ACTG2 GSTM1, GSTM5, UBB, 
GSTM2, GSTM3, GSTM4
Glutathione-mediated 
Detoxification
1.9E-06 5/30 GSTM1, GSTM5, GSTM2, 
GSTM3, GSTM4
Aryl Hydrocarbon Receptor 
Signaling 5.8E-05 7/140
SRC, GSTM1, GSTM5, 
GSTM2, GSTM3, GSTM4, 
NEDD8
Endocytosis-related pathways:
Caveolar-mediated Endocytosis 
Signaling 1.6E-03 4/72 COPA, COPG1, ACTG2 SRC
Clathrin-mediated Endocytosis 
Signaling 1.9E-03 6/185 ARPC2, AP2A1, ACTG2 UBB, SRC, CD2AP
Cell-ECM interactions, cytoskeletal remodeling, cell adhesion -related pathways:
Remodeling of Epithelial 
Adherens Junctions 7.9E-06 6/68
ARPC2, ACTN2, ACTN1, ACTN4, 
ACTG2
SRC
Epithelial Adherens Junction 
Signaling 7.4E-05 7/146
ARPC2,ACTN2, MYH10, ACTN1, 
ACTN4, ACTG2
SRC
Integrin Signaling 8.7E-05 8/202 Activated (2.12) ARPC2,MYLK, ACTN2, ACTN1, 
ACTN4, ACTG2
SRC, VASP
Actin Cytoskeleton Signaling 1.4E-04 8/217 ARPC2, GSN, MYLK, ACTN2, 
MYH10, ACTN1, ACTN4, ACTG2
Paxillin Signaling 7.4E-04 5/102 Activated (1.34) ACTN2, ACTN1, ACTN4, ACTG2 SRC
Regulation of Cellular 
Mechanics by Calpain Protease 6.8E-04 4/57 ACTN2, ACTN1, ACTN4 SRC
Angiogenesis -related pathways:
VEGF Signaling 4.4E-04 5/91 Activated (1.34) ACTN2, ACTN1, ACTN4, ACTG2 SRC
Other pathways:
Leukocyte Extravasation 
Signaling 4.8E-04 7/198
Activated (1.89) ACTN2, ACTN1, ACTN4, GNAI3, 
ACTG2
SRC, VASP
Germ Cell-Sertoli Cell Junction 
Signaling 9.1E-04 6/160
GSN, ACTN2, ACTN1, ACTN4, 
ACTG2
SRC
Sertoli Cell-Sertoli Cell Junction 
Signaling 1.5E-03 6/178 ACTN2, ACTN1, ACTN4, ACTG2 SRC, PRKAG2
Protein Ubiquitination Pathway 7.6E-05 9/255 PSMD12, PSMA7,PSMA2,PSMB2, PSMB3, UBE2D3 UBB,UCHL3, HSPE1
The findings were prioritized based on the significance level and number of associated proteins (≥ 3). The latter’s (e.g. associated proteins) trend of expression (up- or down- 
regulated) in MIBC versus NMIBC is indicated. Pathways were generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, www.
qiagen.com/ingenuity). 
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metabolism [e.g. enzymes such as UTP--glucose-1-
phosphate uridylyltransferase (UGP2), glucose-6-
phosphate 1-dehydrogenase (G6PD), bisphosphoglycerate 
mutase (BPGM)] and endocytosis (e.g. SEC22B, subunits 
of coatamer, Protein ERGIC-53). Of note, many of 
the proteins (36 out of the 97) that were included in the 
interactome network were not mapped to pathways. This 
includes proteins that have not been previously investigated 
Figure 1: Schematic representation of the MS data analysis workflow. A total of 11 bladder cancer tissue proteomic profiles 
were generated and analyzed using two independent approaches. This includes analysis using Proteome Discoverer and Trans Proteomic 
Pipeline followed by quantification based on peak area and spectral counting (i.e. APEX), respectively. Following consolidation of the 
individual proteomics profiles, proteins identified in at least 60% of samples of at least one group (pTa/pT2+) were considered in differential 
expression analysis. For those, statistical analysis was performed to identify disease-associated proteins (p < 0.05). A total of 60 proteins 
were found to be significantly altered according to both approaches. The overlap increases to 144 proteins, when considering proteins found 
to be differentially expressed (statistically significant level) by at least one approach and exhibiting the same regulation trend based on the 
other quantification approach (up/down-regulation by at least 1.5 fold). These latter 144 proteins were further analyzed by pathway and 
interactome approaches.
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Figure 2: Verification of proteomics findings using immunohistochemistry. (A) Stained sections and (B) quantification 
results for (i) FUCA 1, (ii) PGRMC1 (iii) BROX and (iv) PSMD12 from control, pTa, pT1 and pT2+ human samples are presented. 
Immunohistochemistry analysis was performed using tissue microarrays (total n = 30 including 6 controls, 8 pTa, 8 pT1, 8 pT2+). For each 
protein, the exact number of tissue sections included for the quantification is presented in the figure. Quantification of the staining intensity 
was performed using the Image J software. Mean staining intensities and standard deviations per analyzed group are presented. Statistical 
analysis was performed using an independent sample t-test. 
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in BC tissue specimens, such as FUCA1, PGRMC1 
and PSMD12 [confirmed by immunohistochemistry 
(IHC) as detailed above], but also trans-Golgi network 
integral membrane protein 2 (TGOLN2), transmembrane 
glycoprotein NMB (GPNMB), and TGFBI. 
Collectively, the molecular processes (the 
aforementioned: protein synthesis, degradation, 
glutathione detoxification etc.,  shown in Table 1) were 
further shortlisted based on their predicted activation score 
(z-score using Ingenuity Pathway Analysis), significance 
level and agreement in the fold change direction of protein 
findings mapped to these pathways. Among the top 20 
shortlisted pathways (based on the significance level), 
eIF2 signaling (ranked as 2nd based on the significance 
level) was characterized by the highest activation z-score. 
Additionally, all detected proteins involved in this pathway 
were up-regulated in MIBC versus NMIBC. Interestingly, 
eIF2 signaling partially overlaps with the mTOR pathway, 
which is under investigation in the context of BC, with 
mTOR inhibitors being tested as potential targets for 
BC therapeutic intervention [49]. Given, in addition, 
the existing interest on protein synthesis as a source of 
promising anticancer drugs [50], we shortlisted pathways 
related to protein synthesis for further investigation, 
focusing on eIF2 and mTOR signaling. Among the 
proteins indicated by the tissue proteomic analysis, 
EIF3D, not earlier associated with BC, was overexpressed 
in MIBC versus NMIBC (Supplementary Figure 2) and 
was selected as candidate for further investigation.
Lentivirus-mediated RNAi knockdown of EIF3D 
in T24M cells
In order to investigate the therapeutic impact 
of EIF3D in BC progression, we performed its stable 
knockdown through lentivirus-mediated RNA interference, 
in the metastatic T24M BC cell line (given that enhanced 
expression of this protein was observed in MIBC). T24M 
cells were transduced with the shEIF3D lentivirus, while 
shscramble lentivirus-transduced and/or untransduced 
T24M cells were used as controls. The knockdown 
efficiency was assessed 4 days after the transduction at 
the RNA level by real-time PCR and at the protein level 
by Western blot analysis. As shown in Figure 4, EIF3D 
expression was significantly reduced at the mRNA level 
by 82% ± 10% in T24M shEIF3D cells compared to T24M 
cells shscramble (p ≤ 0.001, Student’s t-test) and at the 
protein level by 64.6% ± 2.46%, respectively (p ≤ 0.01, 
Student’s t-test). No significant differences were detected 
between T24M shscramble and T24M untransduced cells 
Figure 3: Interactome network of proteins altered during bladder cancer invasion. Functional annotations of the proteins 
included in the interaction network was conducted using Gene Ontology Annotation (UniProt-GOA) Database [123]. Proteins involved in 
protein degradation/protein synthesis clusters are marked in red circles. 
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either at the EIF3D RNA or at the protein level (p > 0.05, 
Student’s t-test).
EIF3D knockdown attenuates the tumorigenic 
properties of T24M cells
To elucidate the possible impact of EIF3D on BC, 
we further investigated the impact of its knockdown onto 
the malignant phenotype of T24M cells, including impact 
on cell proliferation, migration and colony forming 
ability in vitro and tumor growth in NOD/SCID T24M 
xenografts. As shown in Figure 5A, the stable knockdown 
of EIF3D in T24M cells resulted in a 63% decreased 
proliferation rate compared to T24M shscramble cells after 
culture for 3 days (0.282 ± 0.115 au versus 0.543 ± 0.058 
au; p ≤ 0.0001, Student’s t-test) and in a 51% decrease 
after 4 days (0.367 ± 0.133 au versus 0.617 ± 0.034 au; 
p ≤ 0.0001, Student’s t-test), respectively. The data from 
both time points were normalized to the measurements 
from day 0 (0.139 ± 0.010 au for T24M shscramble and 
0.133 ± 0.007 au for T24M shEIF3D). No significant 
difference was observed between T24M shscramble and 
T24M untransduced cells. A significant reduction was 
also observed in the migratory capacity of T24M cells 
towards their conditioned media (CM) following EIF3D 
knockdown compared to T24M shscramble cells (80 ± 19 
cells versus 164 ± 21 cells; p ≤ 0.001, Student’s t-test), 
(Figure 5B), whereas, no significant difference in the 
migration of T24M shscramble and T24M untransduced 
cells was detected. With respect to T24M colony forming 
ability (Figure 5C), no significant difference in the 
number of colonies formed by T24M shEIF3D and T24M 
shscramble cells (23 ± 2 versus 22 ± 3; p = 0.86, Student’s 
t-test) was observed. Nevertheless, the diameter of the 
colonies was remarkably decreased in the former (56.459 
± 10.965 pixels versus 100.362 ± 17.516 pixels; p ≤ 0.01, 
Student’s t-test), indicating impaired colony growth. These 
findings clearly indicate that EIF3D has a significant 
influence on the in vitro properties of T24M cells such as 
proliferation, migration and colony forming ability. 
Based on these in vitro results, the impact of EIF3D 
knockdown was further investigated in vivo. T24M 
(n = 12), T24M shscramble (n = 12) and T24M shEIF3D 
(n = 14) tumor bearing mice were generated and examined 
for tumor growth over a period of at least 60 days. A 
significantly reduced tumor volume (17.41 ± 11.88 mm³) 
was observed in the T24M shEIF3D mice compared to the 
T24M (110.03 ± 43.13 mm³; p ≤ 0.0001, Student’s t-test) 
or the T24M shscramble (98.32 ± 50.59 mm³; p ≤ 0.001, 
Student’s t-test) tumor bearing mice (Figure 6A). 
The expression levels of EIF3D were further analysed 
in the excised tumors from all groups, 60 days after the 
injections, at the RNA level by real-time PCR and at 
the protein level by Western blot analyses. As shown 
Figure 4: Evaluation of EIF3D knockdown in T24M cells at the RNA and protein level. (A) Bar graph representing the 
downregulation of EIF3D in T24M shEIF3D cells in comparison to T24M shscramble and untransduced T24M cells analysed by real-time 
PCR. The data were normalized to the human GAPDH reference gene and then to the control T24M untransduced cells. (B) Western blot 
analysis for EIF3D in cell extracts derived from T24M, T24M shscramble and T24M shEIF3D cells. (C) Bar chart showing data from the 
quantification analysis of EIF3D protein bands detected in T24M, T24M shscramble and T24M shEIF3D. The quantification of the proteins 
was performed by using the Quantity One software (BioRad) and the results were normalized to β-Actin loading control and then to the 
T24M untransduced cells. The values represent the means ± SD from three independent experiments performed in duplicate (two-tailed 
Student’s t-test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). 
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in Figure 6B, EIF3D was significantly reduced at the 
mRNA level by 45% ± 2.6% in T24M shEIF3D compared 
to T24M shscramble tumors (p ≤ 0.05, Student’s t-test) 
whereas no significant difference was observed between 
the T24M and the T24M shscramble tumors (p = 0.39, 
Student’s t-test). Additionally, in another set of tumors the 
expression of EIF3D was examined at the protein level 
and, as illustrated in Figure 6C, it was found reduced by 
92.78% ± 6.74% in T24M shEIF3D tumors compared 
to T24M shscramble (p ≤ 0.01, Student’s t-test). No 
significant difference was detected between the T24M and 
the T24M shscramble tumors (p = 0.33, Student’s t-test).
The specificity of the EIF3D findings was further 
supported by testing the impact of knock-down of an 
additional potential target selected from the pathway 
analysis: GTP-binding protein Rheb (RHEB), not 
previously associated with BC, laying upstream of EIF3D 
and considered one of the key molecules activating the 
Figure 5: Impact of EIF3D downregulation on cell proliferation, migration and colony forming ability of T24M cells. 
(A) The knockdown of EIF3D significantly reduced the proliferation rate of T24M cells. The bar graph represents the proliferation rate 
of T24M, T24M shscramble and T24M shRHEB cells at three different time points (Day 0, Day 3, Day 4). The values represent the 
means ± SD from three independent experiments performed in five replicates (two-tailed Student’s t-test, ****p ≤ 0.0001). (B) A significant 
reduction was also observed in the migratory capacity of T24M cells following EIF3D knockdown. The graph illustrates the number of cells 
migrated towards conditioned media derived from T24M cells. The cells were allowed to migrate for 6h toward the CM. Representative 
images of the migrated cells from each condition are displayed below the graph. Magnification: 10×. The values represent the means ± SD 
from two independent experiments performed in duplicate (two-tailed Student’s t-test, ***p ≤ 0.001). (C) The colony forming ability of 
T24M cells was significantly reduced in the case of EIF3D knockdown after 10 days of growth on matrigel. i) The bar graph illustrates 
the mean number of colonies formed by T24M shscramble and T24M shEIF3D cells. ii) Bar graph presenting the average diameter of the 
colonies formed by T24M shscramble and T24M shEIF3D cells. Although no significant difference in the number of colonies was detected, 
a remarkable decrease in the diameter of the colonies was observed upon to EIF3D knockdown. Colony diameters were measured by using 
ImageJ software and their length was given in pixels. iii) Representative images of the colonies formed by T24M shscramble and T24M 
shEIF3D cells. Magnification: 10x. The values represent the means ± SD from two independent experiments performed in duplicate (two-
tailed Student’s t-test, **p ≤ 0.01).
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mTOR complex ([51–54]; Supplementary Figure 1). In 
agreement with our predictions, RHEB was overexpressed 
in invasive versus non-invasive BC by Western blot 
analysis of a small set of tissue specimens (Supplementary 
Figure 3). However, while the lentivirus-mediated RNAi 
knockdown of RHEB (Supplementary Figure 4) decreased 
cell proliferation, migration and colony forming ability 
in vitro (Supplementary Figure 5), no impact on tumor 
growth in vivo was observable (Supplementary Figure 6).
DISCUSSION
The tissue proteome is a rich source of information 
about disease, as tissue is the site of disease initiation and 
progression (reviewed in [55]). In this study, we performed 
LC-MS/MS analysis of tissue specimens from NMIBC 
and MIBC in order to identify proteins significantly altered 
in MIBC and predict additional molecules and pathways 
altered during BC progression. 
Considering the clinical relevance (limited treatment 
options for MIBC and associated significant decrease in 
the survival rate for patients that progress to MIBC), we 
focused our investigation on the comparative analysis 
between muscle-invasive (case group) and non-muscle 
invasive BC (control group). Inclusion of the non-
malignant tissue specimens in the proteomic analysis 
was not possible due to restricted sample availability, 
nevertheless this was performed during the more targeted 
IHC studies (Figure 2). By performing a comprehensive 
proteomic analysis, 144 proteins were found to be 
significantly differentially expressed between MIBC 
and NMIBC samples. Many of these proteins including 
annexin A10 (ANXA10) [40], HPGD [36], actinin alpha 
4 (ACTN4) [42, 43], CTSE [47] and CDH13 [46] and a 
total of 21 others [including transforming growth factor-
beta-induced protein ig-h3 (TGFBI), palladin (PALLD), 
adipogenesis regulatory factor (ADIRF), anterior gradient 
protein 2 homolog (AGR2), keratin type I cytoskeletal 
Figure 6: The knockdown of EIF3D impairs tumor growth in vivo. (A) Tumor growth in T24M, T24M shscramble and T24M 
shEIF3D tumor bearing NOD/SCID mice. Tumor volume was significantly smaller (***p < 0.01, Student’s t-test) in T24MshEIF3D 
compared with T24M or T24M shscramble tumor bearing animals 59 days after the injections. (B) The expression of EIF3D was estimated 
in excised tumors from all groups of mice, 60 days after the injections, at the RNA level. Bar graph representing the downregulation of 
EIF3D in T24M shEIF3D tumors in comparison to T24M shscramble and T24M tumors analyzed with real-time PCR (*p < 0.05, Student’s 
t-test). (C) The knockdown of EIF3D in the tumors was also confirmed 60 days after the injections at the protein level. i) Western blot 
analysis for EIF3D in T24M, T24M shscramble and T24M shEIF3D tumors. ii) Bar chart showing the decreased levels of EIF3D in T24M 
shEIF3D tumors compared to T24M and T24M shscramble tumors (*p < 0.05, Student’s  t-test).
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19 (KRT19)] have already been associated with BC, 
when compared with a database on MIBC [56], serving 
as “positive controls” for the applied approach. Our 
results also revealed numerous proteins that have not 
been associated with or reported in BC tissue, including 
PGRMC1, FUCA1, BROX, coatomer protein complex 
subunit alpha (COPA), or threonyl-TRNA synthetase 
(TARS), with the differential expression of FUCA1, 
BROX, PGRMC1, and PSMD12 having been further 
confirmed in a small set of additional tumors by IHC. 
For the latter (PGRMC1), similar expression trends with 
a decrease in MIBC in comparison to NMIBC have also 
been observed in urine [44, 57]. FUCA1 is a lysosomal 
enzyme responsible for removal of terminal L-fucose 
residues from oligosaccharide chains of glycosylated 
proteins [58]. It has been reported that treatment of highly 
invasive breast cancer cells (MDA MB 231) with alpha-L-
fucosidase significantly decreases their invasive potential 
[59]. Additionally, adhesion of breast cancer cells to ECM 
components was reduced upon treatment with FUCA1 
[60], supporting its inhibitory potential in cancer invasion 
(reviewed in [61]). In contrast to FUCA1, the biological 
function of BROX has not been elucidated yet [62–64]. 
The majority of proteins predicted to be a part of BROX 
interactome (based on STRING analysis) are components 
of the endosomal-sorting complex required for transport 
(ESCTR) system, which may suggest an involvement 
of this factor in sorting and recycling of growth factors. 
Finally, PSMD12 (also known as Rpn5), recently 
predicted to promote proliferation and metastasis based on 
network analysis [65], is a component of the multi-protein 
complex - 26 proteasome, involved in the ATP-dependent 
degradation of ubiquitinated proteins. Specifically, 
PSMD12 is one of the particles that builds the “lid” of 
the proteasome cap, with the latter being involved in the 
de-ubiquitination of targeted proteins (reviewed in [66]). 
Although, numerous inhibitors targeting the proteolytic 
activity of 26S proteasome complex have been investigated 
as potential anti-tumor agents (reviewed in [67, 68]), the 
relevance of PSMD12 in cancer has not been investigated 
yet. It appears that further investigation of the biological 
relevance of these proteins in BC would be of interest. 
An in-depth analysis of the proteomics findings 
revealed that a wide range of the aberrantly expressed 
proteins are involved in cancer hallmark processes such 
as cell cycle, proliferation, cell metabolism, apoptosis and 
furthermore in processes that are associated with cancer 
invasion, such as cytoskeleton remodeling, cell adhesion 
and migration. In silico analysis of the proteomics findings 
at pathway and interactome levels revealed an activation 
of protein synthesis pathways (eIF2 signaling, tRNA 
charging, regulation of eIF4 and p70S6K signaling and 
mTOR signaling), which have been previously reported 
to be deranged in the context of BC [69–79]. Collectively, 
these data enhance the validity of the proteomic analysis, 
and increase the credibility of the novel findings such as 
the observed decrease of FUCA1, BROX, PGRMC1 and 
increase of PSMD12 (also supported by the IHC analysis, 
Figure 2) in MIBC.
Given that protein synthesis pathways were clearly 
predicted to be activated in tumor growth and progression 
[80], they were more thoroughly investigated in order to 
better understand the contribution of individual proteins. 
Cancer cells are characterized by translational alterations 
that increase the rate of protein synthesis, sustaining 
in this way, cancer progression and survival [81–83]. 
One of the most complex and rate-limiting steps in this 
process is translation initiation, in which a great number of 
eukaryotic initiation factors are involved [84, 85]. Aberrant 
expression, mutations and post-translational modifications 
of many translation initiation factors have been 
previously described in different cancer types [50, 80]. 
Among the translation initiation factors, eukaryotic 
initiation factor 3 (eIF3) is the largest and most complex 
component. The human eIF3 translation initiation factor is 
an 800 kDa complex that consists of 13 subunits and acts 
as a scaffold for the assembly of the initiation complex 
[86, 87]. The aberrant expression of eIF3 subunits in 
different cancer types has been previously described in 
numerous studies [88]. In our study, EIF3D subunit was 
found to be up-regulated in MIBC compared to NMIBC 
and the knockdown of this factor resulted in the reduction 
of T24M cell proliferation, migration and colony forming 
ability in vitro, and decreased tumor growth in a xenograft 
mouse model in vivo. These findings are novel in the field 
of BC and demonstrate for the first time that EIF3D may 
promote the progression of this malignancy. Similarly with 
our findings, EIF3D was found to be up-regulated in recent 
studies in other cancer types including prostate cancer [89], 
non-small cell lung cancer [90], colon cancer [91], breast 
cancer [92], renal cell carcinomas [93], melanomas [94] 
and gliomas [95]. In the aforementioned studies, it was 
reported that the depletion of EIF3D resulted in cell cycle 
arrest and reduced the proliferation rate and colony forming 
ability of the cancer cells. Furthermore, a decreased 
migratory capacity of the cancer cells upon suppression 
of EIF3D was also described [89, 92]. All the previously 
reported data concerning the EIF3D in other cancer types 
are consistent with our findings. The increasing number of 
studies indicates that increased level of EIF3D in cancer 
may be a common feature in several malignancies. In BC, 
other eIF3 subunits have been investigated and the results 
are in accordance with our data [96, 97]. Theodorescu’s 
group identified eukaryotic initiation factor 3 subunit B 
(EIF3B) expression elevated in human bladder and prostate 
cancers [97]. The depletion of this factor in vitro resulted 
in decreased proliferation rate due to cell cycle arrest at 
the G1/S transition, inhibited cell migration, and in vivo 
delayed tumor growth [97]. In another study, Spilka et 
al. observed that the upregulation of eukaryotic initiation 
factor 3 subunit A (EIF3A) in BC was correlated with 
tumor grade, prompting the authors to suggest that EIF3A 
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could serve as a prognostic biomarker in low grade tumors 
[96]. Knocking down EIF3A decreased proliferation 
rate, and reduced invasion and tumor formation in mice 
[96]. The above data and our findings suggest that BC 
progression may be supported by increased expression 
and activity of the eIF3 complex. Thus, EIF3D could be 
potentially amenable to pharmacological targeting.
So far, therapeutic strategies targeting the 
translational machinery components in cancer focused on 
the eukaryotic translation initiation factor 4F complex and 
specifically the EIF4E subunit (reviewed in [50]). Recent 
evidence, however, supports the existence of an alternative 
cap-dependent translation mechanism, independent from 
EIF4E [98]. This recently described model, suggests that 
translation is driven by EIF3D, through recognition of 
the 5ʹ mRNA cap in a subset of mRNAs (such as the cell 
proliferation regulator c-Jun) that are eIF3-specialized and 
where EIF4E recruitment is blocked [98]. This gives rise 
to another layer of cap-dependent translation. Collectively, 
our results suggest that the development of inhibitors for 
the subunits of the eIF3 complex (EIF3B, EIF3D) may 
be a promising research avenue toward pharmaceutical 
intervention in BC especially in cases where EIF4E is 
apparently missing. 
The predicted activation of the translational 
machinery based on the observed proteomics changes in 
MIBC also included a predicted activation of the mTOR 
pathway. As illustrated in Supplementary Figure 1, the 
in silico analysis of the proteomics findings, predicted 
a hyperactivation state for both the mammalian target of 
rapamycin complex 1 (mTORC1) and mammalian target 
of rapamycin complex 2 (mTORC2) with their negative 
regulator 5′ AMP-activated protein kinase (AMPK) 
detected from the proteomic analysis being down-regulated. 
RHEB is a member of the small Ras GTPase family [99] 
that serves as an upstream activator of mTORC1 [100]. The 
predicted overexpression of RHEB in MIBC compared 
to NMIBC based on the in silico analysis was confirmed 
by Western blot. However, interestingly, inactivation of 
RHEB failed to impact tumor growth in vivo. Existence 
of mechanisms bypassing mTOR inhibition have been 
suggested to explain negative results from respective 
clinical trials (reviewed in [101]). Based on our results, the 
overexpression of downstream proteins in protein synthesis-
related pathways, such as EIF3D, may be contributing to 
the acquired resistance of cancer cells to mTOR inhibition, 
a hypothesis meriting further investigation. 
Collectively, our study represents a comprehensive 
analysis of BC proteome from patients with muscle 
invasive and non- muscle invasive disease providing a 
proteomic component to support molecular integrative 
studies in the future. Functional analysis suggested a 
potential therapeutic effect for EIF3D. This finding 
requires further investigation in animal models, as well 
as in tumor specimens in relation to muscle invasive 
molecular subtypes. Determining EIF3D therapeutic 
potential, especially in tumors where eIF4 inhibitors 
apparently fail, may open up exciting avenues for further 
research toward personalized treatment.
MATERIALS AND METHODS
Patients and tumor characteristics
BC tissue specimens were collected from patients 
undergoing cystectomy or transurethral resection of BC 
in medical centers in Greece (Laikon Hospital, Athens) 
and Germany (Department of Urology and Urological 
Oncology, Hannover Medical School). Sample collection 
was approved by the respective local ethics committees 
(for Athens Ε.S 618–2012 and for Hannover 614–2009), 
and all individuals gave written informed consent. Samples 
from tumor tissue from 11 patients were employed for 
the proteomic analysis including non-muscle invasive 
(stage pTa, n = 5) and muscle invasive bladder cancer 
cases (stage pT2+, n = 6); whereas for the IHC, from a 
total of 8 patients with pTa, 8 with pT1 and 8 patients 
with pT2+. Normal controls (n = 6); corresponded to 
normal adjacent epithelium from patients that underwent 
cystectomy. Tumor stage was determined according to 
TNM classification of malignant tumors [102], whereas 
grading was performed in accordance to World Health 
Organization (WHO) Grading System 2004 [103]. 
Sample preparation
Approximately 20 mg of BC tissue was 
homogenized in 150 μl of lysis buffer (4% SDS, 0.1M 
DTE, 0.1M Tris-HCl pH 7.6) using a blade homogenizer 
(three cycles of 30–40 s) followed by sonication (15 s 
per sample). Undissolved materials were removed 
by centrifugation at 16,000 rcf for 10 min. Protein 
concentration was determined by the Bradford assay 
(BioRad, California, USA). Protein extracts (200 µg) 
were processed using filter aided sample preparation 
(FASP) as described previously [104], with some minor 
modifications [105]. Briefly, buffer exchange was 
performed in Amicon Ultra Centrifugal filter devices 
(0.5 ml, 30 kDa MWCO; Merck, NJ, USA) at 16,000 
rcf for 15 min at room temperature. The protein extract 
was mixed with urea buffer (8M urea in 0.1M Tris-HCl 
pH 8.5) and centrifuged. The concentrate was diluted with 
urea buffer and centrifugation was repeated. Alkylation of 
proteins was performed by adding 0.05M iodoacetamide 
in urea buffer followed by 20 min incubation in the dark 
and centrifugation at 16,000 rcf for 10 min. Additional 
series of washes were conducted with urea buffer (2 times) 
and ammonium bicarbonate buffer (50 mM NH4HCO3 pH 
8, 2 times). Tryptic digestion was performed overnight 
using trypsin to protein ratio 1:100. Peptides were eluted 
by centrifugation at 16000 rcf for 10 min, lyophilized and 
stored at –80°C until further use.
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LC-MS/MS analysis
Tryptic digests were loaded onto a Dionex Ultimate 
3000 RSLS nano flow system (Dionex, Camberly, UK). 
After loading onto a Dionex 0.1 × 20 mm 5 μm C18 nano 
trap column at a flow rate of 5 μl/min in 0.1% formic 
acid and 2% acetonitrile, samples were applied onto an 
Acclaim PepMap C18 nano column 75 μm × 50 cm, 2 μm 
100 Å at a flow rate of 0.3 μl/min. The trap and nano flow 
column were maintained at 35°C. The samples were eluted 
with a gradient of solvent A: 0.1% formic acid versus 
solvent B: 80% acetonitrile starting at 1% B for 5 min 
rising to 5% B at 10 min then to 25% B at 360 min and 
65% B at 480 min.
The eluent was ionized using a Proxeon nano 
spray ESI source operating in positive ion mode into 
an Orbitrap Velos FTMS (Thermo Finnigan, Bremen, 
Germany). Ionization voltage was 2.6 kV and the capillary 
temperature was 200°C. The mass spectrometer was 
operated in MS/MS mode scanning from 380 to 2,000 m/z. 
The top 20 multiply charged ions were selected from each 
scan for MS/MS analysis using CID at 40% collision 
energy. The resolution in MS1 was 60,000 and 7,500 at 
m/z 400 for CID in MS2. 
Data processing and quantification
The raw data from LC-MS/MS analysis were 
evaluated using commercially available Proteome 
Discoverer (PD) v. 1.2 (Thermo Scientific) and open source 
Trans-Proteomic Pipeline (TPP) v. 4.6.3 (Institute for 
Systems Biology, Seattle Proteomic Center; http://tools.
proteomecenter.org/wiki/index.php?title=Software:TPP). 
Database search was carried out against Human Swiss-
Prot Database [106, 107] (30/10/2013) containing only 
the canonical sequences with 20,277 reviewed entries 
using Sequest [108] and X!Tandem [109] search engines 
in PD and TPP [110, 111], respectively. Both analyses, 
using PD and TPP, were performed using comparable 
parameters including a) precursor mass tolerance 10 
ppm, b) fragment mass tolerance: 0.8 Da, c) fixed 
modification: carbamidomethylation of cysteine, d) variable 
modifications: oxidation of methionine and proline, e) not 
allowing for semitryptic peptides, and f) allowing one 
missed cleavage. Moreover, using TPP, another database 
search was also performed against a concatenated database 
with a shuffled version of decoy database as created using 
COMPASS [112]. Additionally, to generate appropriate 
input files, raw data were converted to mzML format using 
Msconvert (ProteoWizard). Results from TPP were further 
validated using PeptideProphet [113] and ProteinProphet 
[114] which are incorporated in the TPP software. Proteins 
with false positive rate less than 5% were included for 
subsequent quantification. For the analysis in PD, dataset 
was filtered requiring mass deviation below 5 ppm between 
experimental and theoretical mass and only peptides 
characterized by high confidence were included. Peptide 
confidence was assessed based on Xcorr score and charge. 
Peptides having the charge of 1, 2, 3, >4 and the respective 
XCorr value higher than 1.5, 2, 2.5, 3 were defined as high 
confidence. In both cases, protein grouping was disabled 
and proteins identified by a single peptide (unique or shared 
with other proteins) were also considered. 
Quantification analysis was performed using 
peak area-based quantification (for PD) and spectral 
counting (for TPP). Given these stringent conditions of 
data analysis, employing two independent approaches 
for quantification, all peptides (unique or shared with 
other proteins) assigned to a protein were taken into 
consideration in order to maximize proteome coverage. 
Of note, the inclusion of non-unique peptides seems to 
not have a significant impact on quantification results 
(as revealed by correlation analysis performed upon 
inclusion/exclusion of shared peptides, data not shown). 
The peak area-based quantification uses precursor ions 
to assess the relative abundance of identified proteins in 
the label-free data. For each precursor ion, peak area (i.e. 
area under the curve) is calculated from the extracted ion 
chromatogram during data processing in PD by using the 
Precursor Ions Area Detector node. Protein quantification 
was based on the protein area values calculated as an 
average of the area for three most abundant peptides. 
When the peptide was not identified in the particular 
sample, the missing values were replaced with zero. Part 
per million (ppm)-normalization was conducted for the 
proteins identified in individual samples according to 
the following formula: Normalized peak area = (Peptide 
peak area/Total peak area) × 106. The spectral count-
based quantification was performed using the Absolute 
Protein Expression Quantification algorithm (APEX), as 
described previously [115]. The normalized APEX score 
was obtained by dividing individual protein values by 
the total APEX score for each sample. The mean protein 
abundance per groups (pTa or pT2+) and SD were then 
calculated. The changes in the relative abundance were 
represented by the fold change, calculated as a ratio for 
muscle invasive (pT2+) to non-muscle invasive cases 
(pTa). In both approaches, only proteins consistently 
reported in ≥ 60% of the samples (at least in one group: 
pTa and/or pT2+) were considered as credible and 
included for further statistical assessment.
Statistical analysis
Statistical analysis was performed using the SPSS 
Statistical Software (SPSS 17.0, IBM). The distribution 
of the data was evaluated using the Kolmogorov-Smirnov 
test. Since a normal distribution was observed, independent 
sample t-test was applied. Proteins with a p-value below 
0.05 were considered as statistically significant. 
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Bioinformatics analysis
The impact of the differentially expressed proteins 
was further evaluated in the context of pathway as well 
as interactome network analyses. The pathways were 
generated using QIAGEN’s Ingenuity Pathway Analysis 
(IPA®, QIAGEN Redwood City, www.qiagen.com/
ingenuity). Statistical analysis was conducted by using 
right-tailed Fisher’s exact test and pathways with a 
p-value below 0.05 were considered as significant. The 
protein interaction network was created using STRING v. 
9.1 (Search Tool for the Retrieval of Interacting Genes/
Proteins, http://string-db.org/) using default settings [116].
Immunohistochemistry on tissue microarrays 
Verification of proteomics findings was performed 
using immunohistochemistry (IHC) staining on tissue 
microarrays, as described previously [105]. Briefly, 
immunochistochemical analysis was performed for (i) 
BRO1 domain-containing protein BROX (BROX; rabbit 
polyclonal anti-BROX, Novus Biologicals, dilution 1:300), 
(ii) Membrane-associated progesterone receptor component 
1 (PGRMC1; rabbit polyclonal anti-PGRMC1, Proteintech, 
dilution 1:50), (iii) Tissue alpha-L-fucosidase (FUCA1; 
rabbit polyclonal anti-FUCA1, Proteintech, dilution 
1:100) and (iv) 26S proteasome non-ATPase regulatory 
subunit 12 (PSMD12; rabbit polyclonal anti-PSMD12, 
Novus Biologicals, dilution 1:400). Staining intensity was 
quantified using ImageJ software as described [105]. 
Cell lines and conditioned media
The human embryonic kidney cell line 293T and the 
human fibrosarcoma cell line HT1080 were obtained from 
American Type Culture Collection (ATCC). The human 
bladder cancer cell line T24M, represents the metastatic 
variant of T24 cells and was developed by our group after 
following cycles of subcutaneous injections of T24 cells in 
mice and re-isolation and culture of metastatic cells in vitro 
as previously described [117]. All the cell lines were 
cultured in DMEM media (Gibco-BRL, Paisley, Scotland 
UK) supplemented with 10% fetal bovine serum (FBS; 
Gibco-BRL, Paisley, Scotland UK) and 1% Penicillin-
Streptomycin (Pen-Strep; Gibco-Invitrogen) at 37°C in 5% 
CO2 under sterile conditions. For the preparation of the 
conditioned media (CM), T24M cells were incubated in 
DMEM supplemented with 2% FBS, 1% Pen-strep for 48h 
at 37°C in 5% CO2. Subsequently, the CM was collected 
after centrifugation at 2000 rcf for 10 min in order to 
remove dead cells and debris, as described before [118].
Production of shRNA lentiviruses and 
transduction of the target cell lines
The knockdown study was performed 
using lentiviral-mediated RNA interference. The 
lentiviral vectors with the sequences for the shRNAs 
were purchased from the Erasmus Center for 
Biomics. The shRNA sequences targeting EIF3D 
and RHEB were 5′-CCGGCCTCAGACATA 
CTCCATAGATCTCGAGATCTATGGAGTATGTCTGA 
GGTTTTTG-3′, respectively. A scrambled shRNA 
(shscramble) was used as control, as previously described 
[119]. For the lentivirus production, a four plasmid 
system was used for the transient transfection of 293T 
cells as previously described [120, 121], followed by 
concentration with Amicon Ultra Centrifugal Filters-100K 
Units (Merck Millipore). The titers of the concentrated 
lentiviruses were determined after infection of HT1080 
cells with serial dilutions of the viral stock. The titers 
were estimated at 5×108 – 109 infection units (IU)/ml. 
The lentiviruses were then used for the transduction of the 
target cell line T24M. As control T24M cells transduced 
with a lentivirus for shscramble was used. The knockdown 
effect was evaluated at the RNA level by real-time PCR 
and at the protein level by Western blot analyses as 
described in the following sections.
Real-time PCR 
Total RNA was isolated from T24Mshscramble, 
T24MshEIF3D and T24MshRHEB cells 4 days after 
the transduction and from untransduced T24M cells 
using the TRI Reagent (Sigma-Aldrich) according to the 
manufacturer’s instructions. Total RNA was also isolated 
from T24M, T24Mshscramble, T24MshEIF3D and 
T24MshRHEB tumors from the respective groups of mice 
by using the same protocol. For the cDNA synthesis 1μg 
of total RNA was used as starting material for SuperScript 
II reverse transcriptase (Invitrogen). Real-time PCR was 
performed on a SaCycler-96 (Sacace Biotechnologies) 
using the SYBR Green master mix (Kapa Biosystems) 
and the following primers: EIF3D (forward): 5ʹ-CAGCG 
GAATCGAATGAGATTTGC-3ʹ EIF3D (reverse): 5ʹ-GTT 
TGGCACTCTTAGGCAGGA-3ʹ, RHEB (forward): 5ʹ-TT 
GTGGACTCCTACGATCCAA-3ʹ, RHEB (reverse): 
5ʹ-GGCTGTGTCTACAAGTTGAAGAT-3ʹ according 
to the manufacturer’s protocol. GAPDH was used as an 
internal control. The relative gene expression analysis was 
performed by implementing the 2–ΔΔCt method.
Western blot analysis
Total cell extracts were obtained from 
T24Mshscramble, T24MshEIF3D and T24MshRHEB 
cells 4 days after the lentiviral transduction and from 
untransduced T24M cells. Total cell extracts were also 
obtained from T24M, T24M shscramble, T24M shEIF3D 
and T24M shRHEB tumors from the respective groups of 
mice. Protein extracts were separated by 10% SDS-PAGE 
under reducing conditions and transferred to Hybond-
ECL nitrocellulose membrane (Amersham Biosciences). 
The membranes were blocked in TBS-0.1% Tween 5% 
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milk for 2 hours at room temperature, then they were 
washed with TBS-0.1% Tween and incubated overnight 
at 4°C with the following primary antibodies: rabbit anti-
human EIF3D (Proteintech, dilution 1:400), mouse anti-
human RHEB (Santa Cruz, dilution 1:500). Membranes 
were washed again as described above and then incubated 
for 2 h at room temperature with secondary antibodies 
conjugated with HRP (anti-rabbit, Amersham, dilution 
1:10,000; anti-mouse, Santa Cruz, dilution 1:2,000). After 
washing membranes with TBS-0.1% Tween, the target 
proteins were detected with an ECL detection kit (Thermo 
Scientific). B-actin was used as a loading control. The 
films were scanned at a GS-800 imaging densitometer 
(BioRad) in transmission mode and densitometry analysis 
of the results was performed using the Quantity One 
software (BioRad). 
MTS cell proliferation assay
T24M, T24Mshscramble, T24MshEIF3D and 
T24MshRHEB cells were seeded in 96-well plates 
at a density of 1,000 cells per well and cultured for 3 
and 4 days, respectively. At the indicated time points 
the recommended amount of MTS reagent (Promega, 
Madison, USA) was added into each well of the 96-well 
plate and the cells were then incubated for additional 3 
hours at 37°C in a humidified, 5% CO2 atmosphere. The 
absorbance was then recorded at 490 nm with a 96-well 
plate reader (SPECTROstar Nano, BMG LABTECH). 
For the calculation of the percentage difference in 
the proliferation rate the following formula was used: 
[(ODday × – ODday 0)/(ODcontrolday × - ODcontrolday 0)] 
×100. Each experiment was performed in five replicates 
and repeated two times.
Colony formation assay
T24M, T24Mshscramble, T24MshEIF3D and 
T24MshRHEB cells were plated at a density of 1000 
cells per well in 96-well plates pre-coated with matrigel 
(BD Biosciences, New Jersey, USA) according to the 
manufacturer’s instructions. The cells were incubated for 
10 days at 37°C in a humidified, 5% CO2 atmosphere. 
Photographs were taken from 5 fields of view (×10 or ×5) 
for each well, using a Leica CTR MIC microscope. The 
number and the size of the colonies were counted by using 
the Image J 1.49v software. Two independent experiments 
were performed, each including three replicates. 
Transwell migration assay
Transwell migration assays were performed as 
previously described [118, 120, 122]. In brief, 5 × 104 
cells T24M, T24Mshscramble, T24MshEIF3D and 
T24MshRHEB were added to the inside compartment 
of transwell inserts with 5μm pores (Corning-Costar, 
Cambridge, MA). As stimulus, CM derived from T24M 
cells was added at the bottom chamber of the transwell 
plate. Cells were allowed to migrate for 6 hours. 
Subsequently, the top of each insert was washed with PBS 
and the cells that had not migrated through the membrane 
were removed with a wet cotton swab. The migrated 
cells at the bottom of the insert were fixed with 4% 
paraformaldehyde (Sigma Aldrich) and stained with eosin-
haematoxylin. The migratory capacity of the cells was 
assessed by counting the number of the cells that passed 
through the pore membrane. Photographs from 5 different 
fields (10x) of each insert were taken using a Leica CTR 
MIC microscope. Stained cells were counted using the 
Image J 1.49v software. Two independent experiments 
were performed, each including two replicates. Statistical 
analysis was performed using Student's t-test.
Animal experiments
The NOD-SCID mice used for the in vivo 
experiments were housed and maintained at the Animal 
Facility of the Biomedical Research Foundation of the 
Academy of Athens. The procedures applied for the animal 
care and treatment were according to the recommendations 
of the Federation of European Laboratory Animal Science 
Associations (FELASA) and also approved by the 
Institutional Animal Care and Use Committee. For the 
development of the tumors, 3.3 × 106 T24M shEIF3D 
(n = 14), T24M shRHEB (n = 13), T24M shscramble 
(n = 12) and T24M (n = 12) cells were administered 
subcutaneously into the tail base of 8–10 weeks old male 
NOD/SCID mice, as described previously [119, 120]. The 
tumor size was measured on a weekly basis by using a 
caliper until the tumors reached an average diameter of 
12–15mm. At that time point the animals were sacrificed 
and tumors, lungs, livers, spleens and kidneys were 
collected. In the presence of tumor ulceration or bleeding 
the mice were sacrificed earlier. 
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